SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Bristol Myers Shares Preliminary Phase 3 ADEPT Data for KarXT

Open-label Phase 3 ADEPT-1 and ADEPT-3 data showed improvements in hallucinations, delusions and disease symptoms.

BMY

Related stories